RxDoctor Payments Data

Vinessa Gaerlan-Finch

Psychiatric/Mental Health · Laguna Niguel, CANPI 1275729329

Payments from drug & device makers

$2,724in general payments, 2019–2025

Across 107 payments — averaging $25.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vanda Pharmaceuticals Inc.$472
  • Otsuka America Pharmaceutical, Inc.$402
  • Lundbeck LLC$350
  • Ironshore Pharmaceuticals Inc.$216
  • Neos Therapeutics, LP$169
  • Teva Pharmaceuticals USA, Inc.$163
  • plus $952 from 14 others

What the payments were for

  • Food & beverage$2,724100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,724 in reported general payments places this provider in the 80th percentile of 2,433 psychiatric/mental health providers in California.

See all psychiatric/mental health providers in California

Medicare billing

Part B allowed, 2024
$40,296
Medicare patients
67
Services billed
439

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lurasidone Hcl11$3,865
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine21$3,203
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine99$2,806
Aripiprazole29$1,242
Bupropion XlBupropion Hcl33$658
Venlafaxine Hcl ErVenlafaxine Hcl25$588
Duloxetine Hcl68$568
Ziprasidone Hcl15$464
Lamotrigine64$389
Mirtazapine28$347
Trazodone Hcl46$279
Fluoxetine Hcl16$274
Citalopram HbrCitalopram Hydrobromide15$269
Methylphenidate Hcl12$245
Escitalopram Oxalate25$216

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Almatica Pharma LLCSertraline Hcl$123$13718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,433 psychiatric/mental health providers in California.

Other psychiatric/mental health in Laguna Niguel

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →